Evidence map›Paper›PMID 33990158›Full record

ArticleLupus2021

Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium.

Samar A Soliman, Anam Haque, Sherene Mason, Larry A Greenbaum, M John Hicks, Chandra Mohan, Scott E Wenderfer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Samar A SolimanDepartment of Biomedical Engineering, University of Houston, Houston TX, USA.
Anam HaqueDepartment of Biomedical Engineering, University of Houston, Houston TX, USA.
Sherene MasonConnecticut Children's Medical Center, Hartford CT, USA.
Larry A GreenbaumEmory University, Atlanta GA, USA.
M John HicksTexas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Chandra MohanDepartment of Biomedical Engineering, University of Houston, Houston TX, USA.
Scott E WenderferTexas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
University of Houston · USBaylor College of Medicine · USConnecticut Children's Medical Center · USEmory University · USMinia University · EGTexas Children's Hospital · US

Funding

Monitoring Disease in LupusR01AR074096 · NIAMS · UNIVERSITY OF HOUSTON · PI CHANDRA MOHAN · 2019 to 2026
$4.5M
NIAMS NIH HHS R01 AR074096
6 · The paper itself

Abstract

objectiveTo evaluate the performance of 4 plasma protein markers for detecting disease activity in childhood-onset systemic lupus erythematosus (SLE) patients.

methodsEighty-three consecutive pediatric patients fulfilling ≥4 ACR criteria for SLE and twenty-five healthy controls were prospectively recruited for serological testing of 4 protein markers identified by antibody-coated microarray screen, namely Axl, ferritin, IGFBP4 and sTNFR2. SLE disease activity was assessed using SLEDAI-2000 score. Fifty-seven patients had clinically active SLE (SLEDAI score ≥4, or having a flare).

resultsThe plasma concentrations of Axl and ferritin were significantly higher in patients with active SLE than inactive SLE. Plasma Axl levels were significantly higher in active renal versus active non-renal SLE patients. Levels of Axl, ferritin and IGFBP4 correlated significantly with SLEDAI scores. Levels of Axl, IFGBP4 and sTNFR2 inversely correlated with plasma complement C3 levels. Only plasma Axl and ferritin levels correlated with degree of proteinuria. These markers were more specific, but less sensitive, in detecting concurrent SLE activity than elevated anti-dsDNA antibody titer or decreased C3. Ferritin and IGFBP4 levels were more specific for concurrent active lupus nephritis than anti-dsDNA or C3. Plasma ferritin was the best monitor of global SLE activity, followed by C3 then Axl, while both Axl and C3 were best monitors of clinical lupus nephritis activity.

conclusionIn childhood-onset SLE patients, plasma ferritin and Axl perform better than traditional yardsticks in identifying disease activity, either global or renal. The performance of these plasma markers should be explored further in longitudinal cohorts of SLE patients.

Indexed as

AdolescentAntibodies, AntinuclearAxl Receptor Tyrosine KinaseBiomarkersChildComplement C3Cross-Sectional StudiesFemaleFerritinsHumansInsulin-Like Growth Factor Binding Protein 4Lupus Erythematosus, SystemicLupus NephritisMaleProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAntibodies, Antinuclearanti-dsDNA autoantibodyAXL protein, humanAxl Receptor Tyrosine KinaseBiomarkersComplement C3FerritinsIGFBP4 protein, humanInsulin-Like Growth Factor Binding Protein 4Proto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesReceptors, Tumor Necrosis Factor, Type IIbiomarkerskidney diseaseslupus erythematosusLupus nephritispediatricsproteomicssystemic

Identifiers

PMID33990158
PMCPMC8282643
OpenAlexW3163369100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.